Your browser is no longer supported. Please, upgrade your browser.
ILMN Illumina, Inc. weekly Stock Chart
Illumina, Inc.
IndexS&P 500 P/E61.03 EPS (ttm)5.77 Insider Own0.40% Shs Outstand147.00M Perf Week3.77%
Market Cap51.74B Forward P/E45.88 EPS next Y7.67 Insider Trans-14.55% Shs Float146.46M Perf Month17.08%
Income862.00M PEG2.87 EPS next Q1.42 Inst Own92.40% Short Float1.95% Perf Quarter11.62%
Sales3.40B P/S15.23 EPS this Y-5.10% Inst Trans0.55% Short Ratio3.10 Perf Half Y13.20%
Book/sh27.11 P/B12.98 EPS next Y14.61% ROA12.60% Target Price345.71 Perf Year21.84%
Cash/sh24.59 P/C14.31 EPS next 5Y21.26% ROE23.50% 52W Range268.62 - 372.61 Perf YTD17.34%
Dividend- P/FCF62.86 EPS past 5Y44.40% ROI13.60% 52W High-4.21% Beta1.07
Dividend %- Quick Ratio3.30 Sales past 5Y18.60% Gross Margin69.10% 52W Low32.87% ATR7.82
Employees7300 Current Ratio3.70 Sales Q/Q8.20% Oper. Margin25.60% RSI (14)73.63 Volatility1.70% 2.31%
OptionableYes Debt/Eq0.44 EPS Q/Q11.30% Profit Margin25.10% Rel Volume0.90 Prev Close351.94
ShortableYes LT Debt/Eq0.28 EarningsJul 25 AMC Payout0.00% Avg Volume918.31K Price356.92
Recom1.90 SMA209.63% SMA5011.41% SMA20012.65% Volume553,219 Change1.42%
May-30-19Initiated Wolfe Research Outperform
Jan-03-19Upgrade UBS Neutral → Buy
Oct-09-18Initiated UBS Neutral
Aug-07-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-31-18Reiterated Canaccord Genuity Buy $330 → $340
Feb-05-18Upgrade Citigroup Neutral → Buy
Jan-31-18Upgrade First Analysis Sec Equal-Weight → Overweight $277
Jan-05-18Initiated BTIG Research Neutral
Jan-05-18Downgrade William Blair Outperform → Mkt Perform
Jan-02-18Upgrade Wells Fargo Market Perform → Outperform
Oct-25-17Upgrade Robert W. Baird Neutral → Outperform $184 → $228
Oct-23-17Upgrade Janney Sell → Neutral
Oct-23-17Upgrade Deutsche Bank Hold → Buy $195 → $250
Sep-26-17Resumed Goldman Neutral $200
Aug-07-17Upgrade Canaccord Genuity Hold → Buy $170 → $215
Aug-02-17Upgrade First Analysis Sec Underweight → Equal-Weight
Apr-26-17Reiterated Cantor Fitzgerald Neutral $155 → $170
Mar-20-17Upgrade Leerink Partners Mkt Perform → Outperform
Feb-01-17Reiterated UBS Buy $180 → $185
Jan-18-17Initiated Deutsche Bank Hold $160
Jun-20-19 09:18AM  5 Top Rate-Sensitive Stocks to Buy Amid Fed's Rate Cut Hints Zacks
Jun-19-19 06:41PM  46 and You: Genetic Testing = Giant Growth Market Zacks
09:15AM  They Meet, We Rally Zacks
Jun-18-19 05:45PM  Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks
10:09AM  Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal
Jun-17-19 04:05PM  Illumina Wins Infringement Suit Against Ariosa Diagnostics, Inc. Business Wire
Jun-14-19 11:02AM  Moving Average Crossover Alert: Illumina Zacks
09:30AM  GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks
09:23AM  Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion Zacks
Jun-12-19 05:50PM  Illumina (ILMN) Gains As Market Dips: What You Should Know Zacks
10:03AM  The Zacks Analyst Blog Highlights: American International, Arconic, Hasbro, Illumina and Jefferies Zacks
Jun-11-19 07:47AM  5 Top S&P 500 Stocks to Fly High Despite Market Volatility Zacks
07:17AM  Better Buy: Illumina vs. Guardant Health Motley Fool
Jun-10-19 08:19PM  Heres What Hedge Funds Think About Illumina, Inc. (ILMN) Insider Monkey
Jun-09-19 12:15PM  3 Healthcare Stocks I'd Buy Right Now Motley Fool
Jun-07-19 04:43PM  Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend traders to sell the rally Yahoo Finance Video +5.31%
Jun-06-19 05:45PM  Illumina (ILMN) Gains But Lags Market: What You Should Know Zacks
01:55PM  Top 5 Stocks in the Fight Against Cancer Motley Fool
Jun-05-19 09:44AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne Zacks
Jun-04-19 03:02PM  Is Illumina, Inc.'s (NASDAQ:ILMN) ROE Of 20% Impressive? Simply Wall St.
02:12PM  5 Biotech Stocks to Buy Right Now Zacks
09:00AM  Illumina Introduces Expanded Version of VeriSeq NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions Business Wire
May-30-19 06:53AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
May-29-19 04:05PM  Illumina to Webcast Upcoming Investor Conference Presentation Business Wire
09:30AM  GILD or ILMN: Which Is the Better Value Stock Right Now? Zacks
May-28-19 11:18AM  Why Illumina (ILMN) Could Be an Impressive Growth Stock Zacks
09:47AM  Illumina,, Microsoft, Facebook and Oracle highlighted as Zacks Bull and Bear of the Day Zacks
08:46AM  The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer Zacks
05:43AM  Bull of the Day: Illumina (ILMN) Zacks
May-25-19 09:31AM  Illumina (ILMN) Down 2.1% Since Last Earnings Report: Can It Rebound? Zacks
May-24-19 09:25AM  3 Stocks to Win Big in the Fight Against Cancer Zacks
May-23-19 09:30AM  Has Illumina (ILMN) Outpaced Other Medical Stocks This Year? Zacks
08:15AM  3 Cancer Treatment Stocks to Buy Right Now Motley Fool
May-21-19 06:11AM  Who's Winning the Race for This $100 Billion Healthcare Market? Motley Fool
May-20-19 07:40AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
May-19-19 12:23PM  3 Healthcare Stocks I'd Buy Right Now Motley Fool
10:53AM  Top 5 Health Care Stocks of 2018 by Performance Investopedia
May-17-19 02:34PM  Final trades: Illumina, Home Depot & Colgate CNBC Videos
May-16-19 10:37PM  UK life science companies show signs of health Financial Times
May-15-19 09:00AM  Illumina Files Patent Infringement Suit Against BGI in Denmark Business Wire
May-14-19 01:50PM  Is Illumina, Inc.'s (NASDAQ:ILMN) CEO Overpaid Relative To Its Peers? Simply Wall St.
May-13-19 09:30AM  GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks
08:41AM  Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks
May-08-19 08:45PM  3 Stocks to Buy and Hold for Decades Motley Fool
02:32PM  Human lifespan could soon pass 100 years thanks to medical tech, says BofA CNBC
01:54PM  Final Trades: Disney, Illumina, Impinj & Gold CNBC Videos
11:00AM  App Store for DNA Fizzles as Health Startup Shifts Strategy Bloomberg
08:03AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
May-07-19 06:00PM  Population Health Study Goes Statewide As University Medical Center of Southern Nevada Serves As Host Site For Enrollment Of 25,000 More Nevadans PR Newswire
09:30AM  Is Illumina (ILMN) Outperforming Other Medical Stocks This Year? Zacks
08:01AM  Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall Zacks
May-05-19 09:00AM  Where Will Illumina Be in 10 Years? Motley Fool
May-03-19 03:06PM  5 Top Stocks to Buy in May Motley Fool
May-02-19 08:06AM  5 Top Stocks to Buy in May Motley Fool
May-01-19 04:05PM  Illumina to Webcast Upcoming Investor Conference Presentation Business Wire
Apr-30-19 04:51AM  Buyback Stocks Badly Lag S&P 500 Amid Mounting Criticism Investopedia
Apr-27-19 08:40AM  Edited Transcript of ILMN earnings conference call or presentation 25-Apr-19 9:00pm GMT Thomson Reuters StreetEvents
Apr-26-19 11:55AM  Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up Zacks
08:02AM  The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug Benzinga
01:51AM  Illumina Inc (ILMN) Q1 2019 Earnings Call Transcript Motley Fool
Apr-25-19 10:00PM  Illumina Hits a Lull in the First Quarter Motley Fool
05:26PM  This Genetics Behemoth Just Outran First-Quarter Earnings Forecasts Investor's Business Daily
04:15PM  Illumina: 1Q Earnings Snapshot Associated Press
04:12PM  Helix Expands Focus to Population Health Solutions and Appoints Illumina Veteran Marc Stapley as CEO PR Newswire
04:05PM  Illumina Reports Financial Results for First Quarter of Fiscal Year 2019 Business Wire
03:00PM  Illumina, Inc. to Host Earnings Call ACCESSWIRE
12:27PM  Illumina Earnings, Revenue Beat in Q1
Apr-24-19 03:01PM  Everything You Need to Know About Investing in Healthcare Motley Fool
Apr-23-19 10:20AM  3 Medical Product Stocks Set to Beat This Earnings Season Zacks
06:00AM  Illumina Reports Its Q1 Results on Thursday: 3 Things You Can Expect Motley Fool
Apr-20-19 02:00PM  Pump the Brakes on the Illumina and Pacific Biosciences Deal Motley Fool
Apr-19-19 02:48PM  Top Gene-Sequencing Stocks for 2019 Motley Fool
11:02AM  5 Top Healthcare Stocks to Buy in 2019 Motley Fool
10:51AM  Are Insiders Selling Illumina, Inc. (NASDAQ:ILMN) Stock? Simply Wall St.
Apr-18-19 01:24PM  Final trades: Darden, Twitter, Illumina, Motorola & Discretionary CNBC Videos
10:33AM  Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-16-19 07:43PM  3 Top Healthcare Stocks to Buy in April Motley Fool
09:09AM  Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings? Zacks
Apr-15-19 02:00PM  Four Companies Could Power The New Genomics ETF ETF Trends
Apr-12-19 12:18PM  Get 40% Annualized Returns With This Merger Arbitrage Stock
07:23AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Apr-11-19 03:33PM  Biotechnology Market on a Tear: 5 ETFs in Spotlight Zacks
Apr-10-19 04:44PM  Global X Launches GNOM ETF to Tap Booming Genomics Space Zacks
Apr-09-19 04:04PM  Illumina to Announce First Quarter 2019 Financial Results on Thursday, April 25, 2019 Business Wire
03:33PM  These Cannabis and China ETFs are Leading the 2019 Rally Investopedia
11:07AM  Why Vertex Pharmaceuticals Could Conceivably Succeed Too Well Motley Fool
10:42AM  Why Illumina Could Be a Health Tech Powerhouse for Your Portfolio Motley Fool
09:53AM  5 Stocks in the Age of Miracles Motley Fool
Apr-08-19 09:12AM  Medtronic's New Data for HVAD System to Boost CRHF Segment Zacks
Apr-07-19 09:05AM  3 High-Growth Genomics Stocks You Can Buy Motley Fool
Apr-04-19 07:22PM  Final Trades: Illumina, Baidu, Adient & Enterprise Products CNBC Videos
07:21PM  Final Trades: Illumina, Baidu, Adient & Enterprise Products CNBC
08:56AM  Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake Zacks
Apr-03-19 09:10AM  Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm Zacks
Apr-02-19 08:28AM  Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks
Apr-01-19 10:27AM  Illumina, Inc.'s (NASDAQ:ILMN) Earnings Grew 14%, Did It Beat Long-Term Trend? Simply Wall St.
Mar-29-19 09:00AM  Illumina Files Patent Infringement Suit Against BGI in Germany Business Wire
Mar-27-19 11:16PM  Were Hedge Funds Right About Fleeing From Illumina, Inc. (ILMN)? Insider Monkey
Mar-26-19 02:00AM  Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues Business Wire
Mar-21-19 04:20PM  Better Buy: Illumina vs. Guardant Health Motley Fool
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ronaghi MostafaSVP & CTOJun 17Option Exercise69.3410,000693,40086,776Jun 19 07:07 PM
Ronaghi MostafaSVP & CTOJun 17Sale349.2810,0003,492,75376,776Jun 19 07:07 PM
FLATLEY JAY TDirectorJun 12Sale334.533,3001,103,949279,216Jun 14 04:00 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanJun 10Sale335.031,260422,13811,945Jun 12 04:05 PM
deSouza Francis APresident and CEOJun 03Sale309.693,000929,08067,936Jun 05 04:34 PM
Dadswell CharlesSVP & General CounselJun 03Sale309.701,220377,8386,866Jun 05 04:27 PM
FLATLEY JAY TDirectorMay 22Sale304.443,3001,004,652282,516May 24 05:22 PM
Ronaghi MostafaSVP & CTOMay 15Option Exercise69.3410,000693,40087,414May 16 08:34 PM
Ronaghi MostafaSVP & CTOMay 15Sale305.4910,0003,054,87677,414May 16 08:34 PM
ARNOLD FRANCESDirectorMay 13Sale307.951,503462,84910,159May 15 04:44 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanMay 10Sale315.321,260397,30313,205May 13 07:42 PM
FLATLEY JAY TDirectorMay 08Sale318.593,3001,051,347285,816May 10 05:50 PM
EPSTEIN ROBERT SDirectorMay 01Option Exercise51.175,000255,8508,256May 03 05:18 PM
EPSTEIN ROBERT SDirectorMay 01Sale310.445,0001,552,1783,256May 03 05:18 PM
deSouza Francis APresident and CEOMay 01Sale310.013,000930,02970,936May 03 05:12 PM
Dadswell CharlesSVP & General CounselMay 01Sale311.7712438,6598,086May 03 05:07 PM
FLATLEY JAY TDirectorApr 24Sale321.963,3001,062,468289,116Apr 26 05:29 PM
FLATLEY JAY TDirectorApr 10Sale317.013,3001,046,133331,668Apr 12 04:33 PM
EPSTEIN ROBERT SDirectorApr 01Option Exercise51.171,00051,1704,256Apr 03 05:28 PM
deSouza Francis APresident and CEOApr 01Sale315.933,000947,78873,746Apr 03 05:25 PM
Dadswell CharlesSVP & General CounselApr 01Sale314.4512438,9928,210Apr 03 05:22 PM
EPSTEIN ROBERT SDirectorApr 01Sale314.451,000314,4503,256Apr 03 05:28 PM
FLATLEY JAY TDirectorMar 27Sale306.933,3001,012,869334,968Mar 29 04:01 PM
FLATLEY JAY TDirectorMar 13Sale306.503,3001,011,450338,268Mar 29 04:01 PM
EPSTEIN ROBERT SDirectorMar 01Option Exercise51.171,00051,1704,256Mar 05 04:57 PM
deSouza Francis APresident and CEOMar 01Sale316.513,000949,51876,746Mar 05 04:58 PM
Dadswell CharlesSVP & General CounselMar 01Sale313.931,220382,9958,334Mar 05 04:56 PM
EPSTEIN ROBERT SDirectorMar 01Sale313.931,000313,9303,256Mar 05 04:57 PM
FLATLEY JAY TDirectorFeb 27Sale300.003,300990,000341,568Mar 01 05:23 PM
Hoyt Aimee LSVP, Chief People OfficerFeb 26Sale304.6329890,7802,297Feb 28 05:30 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 15Sale294.621,260371,21629,420Feb 19 07:02 PM
FLATLEY JAY TDirectorFeb 13Sale293.663,300969,078344,868Feb 14 04:21 PM
Van Oene MarkSVP Chief Commercial OfficerFeb 12Option Exercise0.005,639015,419Feb 14 04:36 PM
Ronaghi MostafaSVP & CTOFeb 12Option Exercise0.009,782079,217Feb 14 04:34 PM
RAGUSA ROBERT PSVP, Global Quality & OpsFeb 12Option Exercise0.004,540015,316Feb 14 04:32 PM
OSTADAN OMEADSVP Mktg, Prod & Strat PlanFeb 12Option Exercise0.009,492033,875Feb 14 04:23 PM
FLATLEY JAY TDirectorFeb 12Option Exercise0.0028,8880358,929Feb 14 04:21 PM
deSouza Francis APresident and CEOFeb 12Option Exercise0.0024,621082,910Feb 14 04:17 PM
Dadswell CharlesSVP & General CounselFeb 12Option Exercise0.004,127011,064Feb 14 04:15 PM
EPSTEIN ROBERT SDirectorFeb 01Option Exercise51.171,00051,1704,256Feb 05 04:45 PM
Dadswell CharlesSVP & General CounselFeb 01Sale280.1112434,7346,879Feb 05 04:44 PM
deSouza Francis APresident and CEOFeb 01Sale282.953,000848,85464,104Feb 05 04:46 PM
EPSTEIN ROBERT SDirectorFeb 01Sale280.111,000280,1103,256Feb 05 04:45 PM
FLATLEY JAY TDirectorJan 23Sale303.533,3001,001,649329,979Jan 25 04:27 PM
FLATLEY JAY TDirectorJan 09Sale296.203,300977,460333,279Jan 11 04:35 PM
EASTHAM KARINDirectorJan 02Option Exercise71.094,000284,36015,838Jan 04 05:03 PM
EPSTEIN ROBERT SDirectorJan 02Option Exercise51.171,00051,1704,256Jan 04 05:05 PM
EPSTEIN ROBERT SDirectorJan 02Sale294.711,000294,7103,256Jan 04 05:05 PM
deSouza Francis APresident and CEOJan 02Sale293.333,000879,99467,104Jan 04 05:04 PM
EASTHAM KARINDirectorJan 02Sale294.085,0001,470,38110,838Jan 04 05:03 PM
Dadswell CharlesSr VP & General CounselJan 02Sale294.7112436,5447,003Jan 04 05:01 PM
FLATLEY JAY TDirectorDec 26Sale273.873,300903,771336,579Dec 28 05:36 PM
FLATLEY JAY TDirectorDec 12Sale334.133,3001,102,629371,559Dec 13 07:26 PM
OSTADAN OMEADEVP Ops, Products, StrategyDec 10Sale321.50644207,04621,613Dec 12 01:59 PM
Stapley MarcEVP Strategy & Corp DevelopmtDec 06Sale329.691,000329,6956,957Dec 07 05:17 PM
EPSTEIN ROBERT SDirectorDec 03Option Exercise51.171,00051,1706,101Dec 04 09:03 PM
EPSTEIN ROBERT SDirectorDec 03Sale343.571,345462,1024,756Dec 04 09:03 PM
Dadswell CharlesSr VP & General CounselDec 03Sale343.57566194,4615,606Dec 04 09:01 PM
deSouza Francis APresident and CEODec 03Sale345.903,0001,037,68863,643Dec 04 09:02 PM
FLATLEY JAY TDirectorNov 28Sale321.803,3001,061,940373,410Nov 30 04:24 PM
OSTADAN OMEADEVP Ops, Products, StrategyNov 23Sale306.74644197,54122,257Nov 27 04:39 PM
FLATLEY JAY TDirectorNov 14Sale312.503,3001,031,250376,710Nov 16 04:09 PM
Ronaghi MostafaSr VP & CTONov 12Option Exercise37.0410,000370,40079,612Nov 14 05:44 PM
Ronaghi MostafaSr VP & CTONov 12Sale314.6310,0003,146,33769,612Nov 14 05:44 PM
Stapley MarcEVP Strategy & Corp DevelopmtNov 07Sale336.681,000336,6806,957Nov 09 04:23 PM
Van Oene MarkSVP Chief Commercial OfficerNov 05Option Exercise29.446,000176,64017,126Nov 07 05:05 PM
Van Oene MarkSVP Chief Commercial OfficerNov 05Sale326.116,8352,228,95010,291Nov 07 05:05 PM
EPSTEIN ROBERT SDirectorNov 01Option Exercise51.171,00051,1706,447Nov 02 05:01 PM
deSouza Francis APresident and CEONov 01Sale310.852,100652,78870,235Nov 02 05:03 PM
EPSTEIN ROBERT SDirectorNov 01Sale311.861,346419,7645,101Nov 02 05:01 PM
FLATLEY JAY TDirectorOct 24Sale310.583,3001,024,914382,304Oct 26 04:35 PM
Ronaghi MostafaSr VP & CTOOct 10Option Exercise37.0410,000370,40080,805Oct 12 04:37 PM
Ronaghi MostafaSr VP & CTOOct 10Sale311.8410,0003,118,42470,805Oct 12 04:37 PM
FLATLEY JAY TDirectorOct 10Sale321.583,3001,061,214385,604Oct 12 04:35 PM
EPSTEIN ROBERT SDirectorOct 01Option Exercise51.171,00051,1706,793Oct 03 04:17 PM
deSouza Francis APresident and CEOOct 01Sale369.612,100776,18372,335Oct 03 04:20 PM
EPSTEIN ROBERT SDirectorOct 01Sale369.151,346496,8765,447Oct 03 04:17 PM
FLATLEY JAY TDirectorSep 26Sale360.813,3001,190,673388,904Sep 28 05:29 PM
FLATLEY JAY TDirectorSep 12Sale351.663,3001,160,478392,204Sep 14 09:25 PM
Ronaghi MostafaSr VP & CTOSep 10Option Exercise37.0410,000370,40080,805Sep 11 05:49 PM
Ronaghi MostafaSr VP & CTOSep 10Sale347.0710,0003,470,70970,805Sep 11 05:49 PM
EPSTEIN ROBERT SDirectorSep 07Option Exercise51.171,00051,1707,139Sep 11 05:45 PM
EPSTEIN ROBERT SDirectorSep 07Sale345.141,346464,5585,793Sep 11 05:45 PM
Stapley MarcEVP Strategy & Corp DevelopmtSep 04Sale352.051,000352,0548,516Sep 06 08:22 PM
deSouza Francis APresident and CEOSep 04Sale353.662,100742,68674,435Sep 06 06:26 PM
Van Oene MarkSVP Chief Commercial OfficerSep 04Sale354.181,091386,41011,126Sep 06 06:09 PM
Ronaghi MostafaSr VP & CTOAug 10Option Exercise37.0410,000370,40080,805Aug 14 04:07 PM
Ronaghi MostafaSr VP & CTOAug 10Sale331.3910,0003,313,86170,805Aug 14 04:07 PM
OSTADAN OMEADEVP Ops, Products, StrategyAug 02Sale320.701,334427,81424,484Aug 06 08:11 PM
Stapley MarcEVP Strategy & Corp DevelopmtAug 02Sale324.801,000324,7987,516Aug 06 08:10 PM
deSouza Francis APresident and CEOAug 01Sale327.412,100687,55576,535Aug 03 03:03 PM
EPSTEIN ROBERT SDirectorJul 23Sale311.15500155,5756,139Jul 24 07:21 PM
deSouza Francis APresident and CEOJul 12Sale300.003,300990,00078,635Jul 13 02:39 PM
Ronaghi MostafaSr VP & CTOJul 10Option Exercise37.047,500277,80078,496Jul 12 07:39 PM
Ronaghi MostafaSr VP & CTOJul 10Sale288.897,5002,166,70170,996Jul 12 07:39 PM
deSouza Francis APresident and CEOJul 02Sale276.142,100579,88782,271Jul 03 06:20 PM
EPSTEIN ROBERT SDirectorJun 21Sale288.45500144,2256,639Jun 22 07:12 PM